Results 201 to 210 of about 356,273 (249)

Artificial intelligence in ovarian cancer: advancing in precision diagnosis and clinical management. [PDF]

Front Immunol
Shao M, Wang T, Ji L, Xu L, Zhang Y, Wang D, Jia C, Chen L, Zhang H, Yan W, Cui X, Tong R.   +11 more
europepmc   +1 more source

Exposure‐adjusted safety and efficacy of GLP‐I and GLP‐1/GIP receptor agonists compared with non‐GLP‐I for weight management and type 2 diabetes: Based on FDA medical and statistical reports of 34 280 safety and 36 312 efficacy subjects

British Journal of Clinical Pharmacology, EarlyView.
Aims This work aimed to contextualize glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and glucose‐dependent insulinotropic polypeptide (GIP) receptor agonists safety and efficacy regarding weight management (WM); we analysed Food and Drug Administration (FDA) Medical Reviews to analyse 14 medications using patient‐exposure year normalization and ...
Aishwarya Prasad, Anshu Arora, Arun Arora, Jeena Vaid, Arif Khan   +4 more
wiley   +1 more source

Immune Landscape and Tumour Heterogeneity in Ovarian Cancer: Insights From Single-Cell RNA Sequencing. [PDF]

J Cell Mol Med
Chen S, Elhessewi GMS, Cai H, Alawad WM, Mishra MK, Sayed U.   +5 more
europepmc   +1 more source

The Shifting Landscape of Debulking Surgery in Newly Diagnosed Advanced Ovarian Cancer. [PDF]

Cancers (Basel)
Tsolakidis D, Zouzoulas D.
europepmc   +1 more source

Cold atmospheric plasma‐mediated tumor microenvironment remodeling for cancer treatment

BMEMat, EarlyView.
Schematic presentation of CAP‐mediated TME remodeling. This review summarizes recent efforts in cold atmospheric plasma (CAP) application in cancer treatment, highlighting the anticancer potential of CAP, molecular mechanisms, and future perspectives for further improvement and clinical translation.
Israr Khan, Qiujie Fang, Cao Fei, Ziyuan Wang, Zhaowei Chen, Guojun Chen, Zhiming Xu, Shu Xu, Zhitong Chen   +8 more
wiley   +1 more source

Identification of ovarian cancer-associated antigens forming complexes with autoantibodies. [PDF]

J Ovarian Res
Fujimori M, Uryu K, Kobayashi M, Sugimoto K, Endo Y, Furukawa S, Soeda S, Kodera Y, Fujimori K, Chiba H.   +9 more
europepmc   +1 more source

Navigating Hope and Illness Cognition in Advanced Ovarian Cancer Patients: A CSM-Based Phenomenological Study. [PDF]

Psychooncology
Long Y, Zhong C, Wen C, He F, Wang Y, Wang C, Xia H, Shi Y, Jin P.   +8 more
europepmc   +1 more source

Re-Thinking Pharmacokinetics in Ovarian Cancer: What Do Organoids Add? [PDF]

Int J Mol Sci
Lima AEC, Nunes M, Xavier CPR, Ricardo S.   +3 more
europepmc   +1 more source

Inhibition of salt-inducible kinases reprograms T cells and antitumor immunity in ovarian cancer. [PDF]

Nat Immunol
Dong H, Ray A, Rotter LK, Wang J, Grabski I, Mewada H, Wang L, Huang K, Tian Y, Meylan M, Barlow G, Yu C, Raundhal M, Yoon SH, Nakhawa S, Ding L, Zhao JJ, Matulonis UA, Foretz M, Wucherpfennig KW, Irizarry RA, Wein MN, Glimcher LH.   +22 more
europepmc   +1 more source

NSDHL as a regulator of lipid peroxidation and ER stress-mediated apoptosis in ovarian cancer. [PDF]

Biol Direct
Shanshan X, Jinshi R, Wanlin C, Yuwan L, Hanye J, Shizhou Y, Weidong F, Huimei Z, Yongmei X, Weiguo L.   +9 more
europepmc   +1 more source